Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer.

[1]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[2]  J. Mate,et al.  Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. , 1993, Oncogene.

[3]  S. Rodenhuis,et al.  K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung , 1993 .

[4]  R L Smith,et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.

[5]  A. Levinson,et al.  Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. , 1993, Science.

[6]  S. Finkelstein,et al.  Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K‐ras‐2 mutation type , 1993, Cancer.

[7]  M. Kris,et al.  Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. , 1993, The Annals of thoracic surgery.

[8]  Johnson Be,et al.  The biology of lung cancer. , 1993, Seminars in oncology.

[9]  K. Sugimachi,et al.  ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.

[10]  A. Malkinson.  Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. , 1992, Cancer research.

[11]  S. Rodenhuis,et al.  Clinical significance of ras oncogene activation in human lung cancer. , 1992, Cancer research.

[12]  S. Rodenhuis,et al.  The ras gene family in human non-small-cell lung cancer. , 1992, Journal of the National Cancer Institute. Monographs.

[13]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[14]  J. Minna,et al.  Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. , 1991, Oncogene.

[15]  G. Capellá,et al.  Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. , 1991, Environmental health perspectives.

[16]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[17]  M. Barbacid,et al.  Activation of ras oncogenes preceding the onset of neoplasia. , 1990, Science.

[18]  M. Cullen,et al.  Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. , 1988, British Journal of Cancer.

[19]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.